Article
A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Antiviral therapy - 1 Jun 2001
Schooley R T, Clumeck N, Haubrich R, Thompson M, Danner S A, van Der Ende M E, Sereni D, Antunes F, Blake D, Myers R E, Tisdale M, Millard J, Mustafa N, Nacci P
Abstract excerpt
OBJECTIVE: To evaluate the antiretroviral activity and safety of multiple escalating doses of amprenavir administered alone, and in combination with abacavir in HIV-1-infected adults. DESIGN: Sixty-two HIV-1-infected subjects were enrolled in a multicentre, open-label, non-randomized, dose-escalating trial. METHODS: Subjects were assigned to one of six dose groups and received amprenavir 300 mg twice daily, 300...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.